Filter by content type
Filter by year
Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 14, 2019 - … enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion … in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical …
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
April 21, 2021 - … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer … Research … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell …
Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 12, 2019 - … enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion … expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study at the Society for Immunotherapy of …
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 15, 2019 - … Update 05/15/19 Earnings Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the … results from the dose escalation phase of the ongoing CLASSICAL-Lung Phase 1b/2 study at the American Association …
Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
April 9, 2019 - … Research (AACR) 04/09/19 General First Interim Results of CLASSICAL-Lung Phase 1b/2 Study Demonstrate Up To 90 Percent Disease … The company presented interim data for its Phase 1b/2 CLASSICAL-Lung study of its pepinemab antibody in combination …
Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
May 13, 2020 - … Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … Annual Meeting … Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
April 27, 2020 - … Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … Virtual Annual Meeting … Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
Vaccinex Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 9, 2020 - … 03/09/20 Earnings On-track to report topline data from CLASSICAL-Lung and SIGNAL clinical trials this year Announces expansion … Clinical Updates: Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung clinical trial . Near topline data in the …
Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
October 26, 2017 - … 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung) … Vaccinex, Inc. Announces the First … and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung) Vaccinex, Inc. Announces the First Patient …
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 - … Earnings Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to … Accomplishments: Presented updated interim data from the CLASSICAL-Lung Phase 1b/2 study of the company’s lead product … . Pepinemab Clinical Updates: Non-Small Cell Lung Cancer - CLASSICAL-Lung Clinical Trial . The company’s ongoing …